Clinical trial
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab…
NCT00193479 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193479 |
|---|---|
| Title | Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma |
| Official title | A Phase II Trial of Brief Duration Combination Chemotherapy and Rituximab With Prophylactic Pegfilgrastim, Followed by Maintenance Rituximab, in Elderly/Poor Performance Status Patients With Large B-Cell Non-Hodgkin's Lymphoma |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Genentech, Inc. Industry Amgen |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkins Lymphoma |
| Intervention type | Drug |
| Interventions | Cyclophosphamide, Mitoxantrone, Vincristine, Prednisone, Rituximab |
| Enrollment | 51 |
| Start date | Apr 1, 2003 |
| Primary completion | Jul 1, 2008 |
| Completion | Feb 1, 2010 |
| First posted | Sep 19, 2005 |
| Last update posted | Mar 3, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: